Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model

Infection and Immunity

Volumn 73, Issue 10, 2005, Pages 6838-6845

  Zhu, Duzhang ^a   Zhang, Ying ^a   Barniak, Vicki ^a   Bernfield, Liesel ^a   Howell, Alan ^a   Zlotnick, Gary ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN G; IRON DEXTRAN; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; P2086 PROTEIN; POLYSACCHARIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; MENINGOCOCCOSIS; MOUSE; MOUSE STRAIN; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED STRAINS; NEISSERIA MENINGITIDIS, SEROGROUP B; RATS;

EID: 25444523998     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.10.6838-6845.2005     Document Type: Article

References (37)

1. Ashton, F. E., L. Mancino, A. J. Ryan, J. T. Poolman, H. Abdillahi, and W. D. Zollinger. 1991. Serotypes and subtypes of Neisseria meningitidis serogroup B strains associated with meningococcal disease in Canada, 1977-1989. Can. J. Microbiol. 37:613-617.
2. Cadoz, M., J. M. Armand, F. Arminjou, R. Gire, and C. Lafaix. 1985. Tetravalent (A, C, Y, W135) meningococcal vaccine in children: immunogenicity and safety. Vaccine 3:340-342.
3. Danve, B., L. Lissolo, M. Mignon, P. Dumas, S. Colombani, A. B. Schyvers, and M. J. Quentin-Millet. 1993. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 12:1214-1220.
4. Eaton, J. W., P. Brandt, J. R. Mahony, and J. L. Lee Jr. 1982. Haptoglobin: a natural bacteristat. Science 215:691-693.
5. Finne, J., M. Leinonen, and H. Makela. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
6. Fletcher, L. D., L. Bernfield, V. Barniak, J. E. Farley, A. Howell, M. Knauf, P. Ooi, R. P. Smith, P. Weise, M. Wetherell, X. Xie, R. Zagursky, Y. Zhang, and G. Zlotnick. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100.
7. Frantz, I. D. 1942. Growth requirements of the meningococcus. J. Bacteriol. 43:757-761.
8. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
9. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1327-1348.
10. Griffith, E., H. J. Rogers, and J. J. Bullen. 1980. Iron, plasmids and infection. Nature 284:508-509.
11. Holbein, B. E. 1980. Iron-controlled infection with Neisseria meningitidis in mice. Infect. Immun. 29:886-891.
12. Holbein, B. E. 1981. Enhancement of Neisseria meningitidis infection in mice. Infect. Immun. 34:120-125.
13. Holbein, B. E., K. W. F. Jericho, and G. C. Likes. 1979. Neisseria meningitidis infection in mice: influence of iron, variations in virulence among strains, and pathology. Infect. Immun. 24:545-551.
14. Kellogg, D. S. Jr., W. L. Peacock, Jr., W. E. Deacon, L. Brown, and C. L. Pirkle. 1963. Neisseria gonorrhoeae. I. Virulence genetically linked to clonal variation. J. Bacteriol. 85:1274-1279.
15. Lang, D. 2001. Safety evaluation of toxin adjuvants delivered intranasally. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health. [Online.] http://www.niaid.nih.gov/dmid/enteric/intranasal.htm.
16. Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, D. Serruto, D. Litt, S. Kroll, J. A. Welsch, D. M. Granoff, R. Rappuoli, and M. Pizza. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
17. Masson, P. L., J. F. Heremans, and C. H. Dive. 1966. An iron binding protein common to many external excretions. Clin. Chim. Acta 14:729-734.
18. Milagres, L. G., S. R. Ramos, C. T. Sacchi, C. E. Melles, V. S. Vieira, H. Sato, G. S. Brito, J. C. Moraes, and C. E. Frasch. 1994. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:4419-4424.
19. Mountzouros, K. T., and A. P. Howell. 2000. Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis. J. Clin. Microbiol. 38:2878-2884.
20. Mountzouros, K. T., K. A. Belanger, A. P. Howell, G. S. Bixler, Jr., and D. V. Madore. 2002. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model. Infect. Immun. 70:6576-6582.
21. Pillai, S., A. Howell, K. Alexander, B. E. Bentley, H.-Q. Jiang, K. Ambrose, D. Zhu, and G. Zlotnick. 2005. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23:2206-2209.
22. Poolman, J. T., P. A. van der Ley, and P. Hoogerhout. 1991. Second generation meningococcal OMP-LPS vaccines. NIPH Ann. 14:233-242.
23. Sacchi, C. T., A. M. Whitney, T. Popovic, D. S. Beall, M. W. Reeves, B. D. Plikaytis, N. E. Rosenstein, B. A. Perkins, M. L. Tondella, and L. W. Mayer. 2000. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J. Infect. Dis. 182:1169-1176.
24. Salit, I. E., E. van Melle, and L. Tomalty. 1984. Experimental meningococcal infection in neonatal animals: models for mucosal invasiveness. Can. J. Microbiol. 30:1022-1029.
25. Saukkonen, K., M. Loinonen, H. Abdillahi, and J. T. Poolman. 1989. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7:325-328.
26. Schimidt, S., D. Zhu, V. Barniak, K. Mason, Y. Zhang, R. Arumugham, and T. Metcalf. 2001. Passive immunization with Neisseria meningitidis PorA specific immune sera reduces nasopharyngeal colonization of group B meningococcus in an infant rat nasal challenge model. Vaccine 19:4851-4858.
27. Schyvers, A. B., and G. C. Gonzalez. 1989. Comparison of the abilities of different protein sources of iron to enhance Neisseria meningitidis infection in mice. Infect. Immun. 57:2425-2429.
28. Schyvers, A. B., and L. J. Morris. 1988. Identification and characterization of the human lactoferrin-binding protein from Neisseria meningitidis. Infect. Immun. 56:1144-1149.
29. Schyvers, A. B., and L. J. Morris. 1988. Identification and characterization of the transferring receptor from Neisseria meningitidis. Mol. Microbiol. 2:281-288.
30. Tebbey, P. W., C. A. Scheuer, J. A. Peek, D. Zhu, N. A. LaPierre, B. A. Green, E. D. Phillips, A. R. Ibraghimov, J. H. Eldridge, and G. E. Hancock. 2000. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine 18:2723-2734.
31. Tikhomirov, E., M. Santamaria, and K. Esteves. 1997. Meningococcal disease: public health burden and control. World Health Stat. Q. 50:170-177.
32. Tondella, M. L., T. Popovic, T. N. E. Rosenstein, D. B. Lake, G. M. Carlone, L. W. Mayer, and B. A. Perkins. 2000. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J. Clin. Microbiol. 38:3323-3328.
33. Toropainen, M., H. Kayhty, L. Saarinen, E. Rosenqvist, E. A. Hoiby, E. Wedege, T. Michaelsen, and P. H. Makela. 1999. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine 17:2677-2689.
34. Weinberg, E. D. 1978. Iron and infection. Microbiol. Rev. 42:45-66.
35. Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Trament, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-521.
36. Yi, K., D. S. Stephens, and I. Stojiljkovic. 2003. Development and evaluation of an improved mouse model of meningococcal colonization. Infect. Immun. 71:1849-1855.
37. Zollinger, W. D., J. Boslego, E. Moran, J. Garcia, C. Cruz, S. Ruiz, B. Brandt, M. Martinez, J. Arthur, P. Underwood, et al. 1991. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH Ann. 14:211-213.